[Checkpoint inhibitor-induced myocarditis]

Autor:	Gulati G; Hjertemedisinsk avdeling, Oslo universitetssykehus, Ullevål, og, Forskning og innovasjonsavdelingen Akershus universitetssykehus, og, Universitetet i Oslo., Tjessem KH; Hjertemedisinsk avdeling, Oslo universitetssykehus, Ullevål., Horndalsveen H; Avdeling for kreftbehandling Oslo universitetssykehus, Ullevål, og, Avdeling for kreftgenetikk, Institutt for kreftbehandling, Oslo universitetssykehus, Radiumhospitalet., Halvorsen S; Hjertemedisinsk avdeling, Oslo universitetssykehus, Ullevål, og, Universitetet i Oslo., Haakensen VD; Avdeling for kreftbehandling Oslo universitetssykehus, Ullevål, og, Avdeling for kreftgenetikk, Institutt for kreftbehandling, Oslo universitetssykehus, Radiumhospitalet.
Jazyk:	norština
Zdroj:	Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke [Tidsskr Nor Laegeforen] 2022 Dec 12; Vol. 142 (18). Date of Electronic Publication: 2022 Dec 12 (Print Publication: 2022).
DOI:	10.4045/tidsskr.21.0817
Abstrakt:	Immunological checkpoint inhibitors have been revolutionary in the treatment of cancer. A rare but serious adverse effect is the development of heart muscle inflammation (myocarditis). The prevalence of this type of myocarditis is increasing as more cancer patients receive treatment with immune checkpoint inhibitors. Knowledge of immune checkpoint inhibitor-induced myocarditis is important to enable early diagnosis and initiation of treatment. In this article we provide a clinical review of this.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu